glp-1 studies GLP1 agonists: current and future landscape of clinical trials for patients with metabolic dysfunction The benefits of GLP-1 drugs
Description
Pfizer has said it expects pills to eventually capture about a third of the obesity drug market, which is predicted to grow to about $130 billion by the end of the decade.
Interview Courtesy | Ankit Kankar #GLP1 #Diabetes #Obesity #Cardiology #Metabolism #Therapeutics #Innovation #Healthcare #Medicine #Research #Pharmacology #Biotechnology #Clinicaltrials #Prevention #Wellness
Why the Stevanato narrative is flawed
RECLAIM CONTROL FROM DAY ONE AND BUILD ON IT: Start activating your bodys natural un-hunger hormone (GLP-1) from the very first week
Jules Greene of Good Sense Research explores what this shift means for food and drink brands and where innovation is urgently needed.
